Andreas Clemens
Andreas Clemens (born May 5, 1966 in Hildesheim) is a German physician.[1] He is an internist, endocrinologist and diabetologist. His main interest is the investigation and development of drugs in the field of cardiology, endocrinology, ophthalmology and very rare diseases.
Andreas Clemens | |
|---|---|
 | |
| Born | May 5, 1966 Hildesheim, Low German, Germany |
| Nationality | German |
| Education | University of Göttingen Kiel University University Hospital Heidelberg University of Mainz University of Freiburg |
| Occupation(s) | Medical Director and Head New Medical Brand Incubator & Rare Disease of Novartis |
| Medical career | |
| Profession | Physician |
| Institutions | Novartis |
Life and work
As part of his scientific activities, he has published more than 130 peer-reviewed articles.[2] He has an H-index of 42.[3] He is a member of the European Association for Vision and Eye Research Foundation.[4] He is also an associate editor (editor) at Contemporary Clinical Trials.[5] Furthermore, he is actively involved in teaching at the Albert Ludwigs University of Freiburg, Germany.[6]
References
- Dabigatranetexilat, ein neuer oraler direkter Thrombininhibitor: Klinische Entwicklung. 2014.
- "Andreas Clemens - Global Head Medical Affairs Strategy AID & IRD". ResearchGate. Retrieved 3 April 2023.
- "Andreas Clemens, MD, PhD".
- "EVER ƒ Members - General Assembly".
- "Editorial Board - Contemporary Clinical Trials - Journal - Elsevier".
- "Vorlesungsverzeichnis anzeigen - Campus Management - HISinOne".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.